Lexeo Therapeutics, Inc. (LXEO)
LXEO moved a median of -0.36% 30 minutes after news, and +0.84% by the close. How LXEO actually reacts to news — the realized, point-in-time move the market made, measured across 366 labeled events over the last three years with zero look-ahead.
LXEO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.10% | 52% | 361 |
| 30-min | -0.36% | 44% | 366 |
| 60-min | +0.15% | 57% | 366 |
| to close | +0.84% | 55% | 366 |
| Middle 50% of LXEO reactions | -1.64% to +1.73% |
|---|---|
| Median reaction (30-min) | -0.36% |
| Measured reactions | 366 |
Half of all Lexeo Therapeutics, Inc. news events land between -1.64% and +1.73% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How LXEO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.17% | 40% | -1.68% |
| Coverage initiations | 36 | +0.84% | 64% | +2.60% |
| Rating reiterations | 53 | -0.18% | 42% | -0.81% |
| Price-target cuts | 12 | +0.74% | 67% | +3.14% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how LXEO ranks against every other measured name →
That’s how LXEO usually reacts — get an email when it moves on news →Email me when LXEO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LXEO's baseline. Nothing else.
Recent LXEO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Lexeo Therapeutics to Participate in the Chardan Healthcare Conference | Press release | GlobeNewswire | -1.83% | -1.83% | |
| Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS) | Press release | GlobeNewswire | +1.18% | +7.10% | |
| Form 8-K Lexeo Therapeutics, Inc. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -2.33% | -1.74% | |
| Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia | Press release | PR Newswire | -1.47% | -13.51% | |
| Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum | Press release | GlobeNewswire | -1.47% | -13.51% | |
| Form 8-K Lexeo Therapeutics, Inc. For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | -1.39% | -5.57% | |
| Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia | Press release | GlobeNewswire | -1.39% | -5.57% | |
| Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September | Press release | GlobeNewswire | +3.36% | +0.42% | |
| Form 10-Q Lexeo Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.14% | +0.62% | |
| Form 8-K Lexeo Therapeutics, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | +0.62% | |
| Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights | Press release | GlobeNewswire | -1.14% | +0.62% | |
| Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy | Press release | GlobeNewswire | +2.67% | -1.11% | |
| Form 8-K Lexeo Therapeutics, Inc. For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +1.35% | -3.22% | |
| Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia | Press release | GlobeNewswire | +4.61% | -1.20% | |
| Form 8-K Lexeo Therapeutics, Inc. For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +7.54% | +3.10% | |
| Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia | Press release | GlobeNewswire | +7.54% | +3.10% | |
| Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference | Press release | GlobeNewswire | -3.00% | -3.86% | |
| Form 10-Q Lexeo Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.17% | +2.00% | |
| Form 8-K Lexeo Therapeutics, Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +3.17% | +2.00% | |
| Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights | Press release | GlobeNewswire | +3.17% | +2.00% | |
| Form 8-K Lexeo Therapeutics, Inc. For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | +1.40% | -0.09% | |
| Form ARS Lexeo Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.40% | -0.09% | |
| Form DEF 14A Lexeo Therapeutics, Inc. For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +1.40% | -0.09% | |
| Form DEFA14A Lexeo Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.40% | -0.09% | |
| Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting | Press release | GlobeNewswire | +3.02% | +3.38% | |
| Form S-8 Lexeo Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -1.54% | -2.05% | |
| Form 10-K Lexeo Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.54% | -2.05% | |
| Form 8-K Lexeo Therapeutics, Inc. For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | -1.54% | -2.05% | |
| Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights | Press release | GlobeNewswire | -1.54% | -2.05% | |
| Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference | Press release | GlobeNewswire | -1.27% | +2.91% | |
| Form 8-K Lexeo Therapeutics, Inc. For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | +2.27% | +1.56% | |
| Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February | Press release | GlobeNewswire | +1.52% | -4.97% | |
| Form 8-K Lexeo Therapeutics, Inc. For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | +2.94% | +0.67% | |
| Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics | Press release | GlobeNewswire | +2.94% | +0.67% | |
| Form 8-K Lexeo Therapeutics, Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.19% | +4.24% | |
| Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy | Press release | GlobeNewswire | -16.84% | -13.43% | |
| Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy | Press release | GlobeNewswire | -0.35% | -4.15% | |
| Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.19% | -0.75% | |
| Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum | Press release | GlobeNewswire | -1.98% | +6.07% | |
| Form EFFECT Lexeo Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.10% | +1.54% | |
| Form 10-Q Lexeo Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.73% | -0.85% | |
| Form 8-K Lexeo Therapeutics, Inc. For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | -0.73% | -0.85% | |
| Form S-3 Lexeo Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | -0.73% | -0.85% | |
| Form S-8 Lexeo Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.73% | -0.85% | |
| Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights | Press release | GlobeNewswire | -0.73% | -0.85% | |
| Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering | Press release | GlobeNewswire | +0.49% | +4.01% | |
| Form 8-K Lexeo Therapeutics, Inc. For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | +0.93% | -4.75% | |
| Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement | Press release | GlobeNewswire | -3.14% | +4.93% | |
| Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -3.14% | +4.93% | |
| Form 8-K Lexeo Therapeutics, Inc. For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | -1.56% | +1.46% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LXEO section they belong to.
Where else LXEO is measured.
LXEO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Lexeo Therapeutics, Inc.'s median reaction calculated?
Every labeled LXEO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 366 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of LXEO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LXEO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.